US · CDIO
Cardio Diagnostics Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Chicago, IL 60642
- Website
- cardiodiagnosticsinc.com
Price · as of 2024-12-31
$1.88
Market cap 11.96M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $44.31 | +2,256.91% |
| Intrinsic Value(DCF) | $5.42 | +188.3% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $296.40 | ||||
| 2022 | $119.10 | $311.51 | $0.00 | $0.00 | $0.00 |
| 2023 | $41.10 | $123.99 | $0.00 | $0.00 | $0.00 |
| 2024 | $13.56 | $44.31 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cardio Diagnostics Holdings, Inc.'s (CDIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $44.31
- Current price
- $1.88
- AI upside
- +2,256.91%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.42
+188.3% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CDIO | Cardio Diagnostics Holdin… | $1.88 | 11.96M | +2,257% | +188% | — | — | -43.50 | 38.15 | 10451.97 | -44.24 | — | 41.20 | 100.00% | -23977.86% | -24028.24% | -133.96% | -296.88% | -111.20% | 0.10 | -448.81 | 13.92 | 12.42 | 0.85 | -5303.00% | 10445.00% | -1653.00% | -1.48% | -7.90 | -191.54% | 0.00% | 0.00% | 1.87% | -42.77 | -66.29 | 10255.42 | 202.22 |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| ADXN | Addex Therapeutics Ltd | $7.28 | 4.81M | +9,333% | +38% | +845% | — | 0.71 | 0.52 | 12.45 | -0.37 | — | 0.52 | 100.00% | -681.82% | 1746.04% | 130.39% | -137.95% | 92.11% | 0.00 | -776.78 | 4.42 | 4.19 | 0.71 | -15000.00% | -7495.00% | -3281.00% | -106.85% | -6.70 | -269.11% | 0.00% | 0.00% | 0.00% | -0.63 | -0.32 | 4.27 | -43.82 |
| BCDA | BioCardia, Inc. | $1.29 | 7.48M | +6,369% | -19% | — | +16,927% | -0.90 | 8.59 | 123.95 | -0.73 | — | 8.59 | -7463.79% | -13794.83% | -13700.00% | 2074.67% | 810.64% | -236.81% | 1.14 | — | 1.13 | 1.02 | 0.18 | -6459.00% | -8784.00% | -1957.00% | -111.72% | -3.46 | 813.78% | 0.00% | 0.00% | 22.70% | -0.72 | -0.72 | 99.47 | -65.68 |
| CELZ | Creative Medical Technolo… | $1.81 | 4.67M | +18,729% | +39% | — | — | -1.12 | 0.97 | 558.52 | -0.04 | — | 1.06 | 60.00% | -52216.92% | -49940.74% | -65.85% | -1515.86% | -63.20% | 0.00 | — | 18.73 | 18.13 | 1.05 | -133.00% | 2222.00% | -3478.00% | -86.29% | -16.18 | -1399.06% | 0.00% | 0.00% | 43.11% | -0.04 | -0.04 | 18.49 | -4.10 |
| NRSN | NeuroSense Therapeutics L… | $0.91 | 22.42M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
- CEO
- Meeshanthini V. Dogan
- Employees
- 13
- Beta
- 2.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.42 ÷ $1.88) − 1 = +188.3% (DCF, example).